查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2068029

全球Remicade生物相似藥市場：市場規模、佔有率、趨勢和成長分析（2026-2034 年）

Global Remicade Biosimilar Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 230 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球Remicade生物相似藥市場預計將從2025年的55.6億美元成長至2034年的423.2億美元，2026年至2034年的複合年成長率（CAGR）為25.29%。該市場正經歷強勁成長，主要得益於對用於治療自體免疫疾病和發炎性疾病的、具有成本效益的生物製藥的需求不斷成長。 Remicade生物相似藥Remicade為類風濕性關節炎、克隆氏症、潰瘍性大腸炎和乾癬等疾病提供治療選擇。不斷上漲的醫療成本和日益成長的治療可及性需求正在推動醫療系統採用生物相似藥。監管機構對生物相似藥核准的支持也進一步促進了市場擴張。

由於生物相似藥在療效和安全性方面與原廠生物製藥相當，且成本更低，因此醫療機構和保險公司正擴大採用生物相似藥。醫生和患者對生物相似藥益處的認知不斷提高，也推動了其應用。保險覆蓋範圍的擴大和有利的醫療保健政策也在促進市場成長。此外，慢性發炎性疾病盛行率的不斷上升也持續推高了對生物製藥的需求。

鑑於醫療保健系統正致力於控制成本並擴大患者獲得先進治療的機會，前景極為樂觀。持續進行的生物相似藥研發項目和監管協調工作預計將加劇市場競爭。隨著擴大醫療服務覆蓋範圍和減輕醫療成本負擔的努力不斷推進，新興市場有望成為重要的成長區域。隨著生物製藥療法使用量的持續成長，Remicade生物相似藥市場預計將持續擴張。

我們的報告經過精心撰寫，旨在為客戶提供有關各個行業和市場的全面且切實可行的見解。每份報告都包含幾個關鍵要素，以便全面了解市場狀況：

市場概覽：有關市場的詳細資訊，包括定義、分類和行業現狀。

市場動態：本節詳細分析影響市場成長的主要促進因素、限制因素、機會和挑戰。本節將檢驗技術進步、監管變化和新興趨勢等因素。

細分市場分析：市場根據產品類型、應用、最終用戶和地區等標準分類為若干清晰的細分市場。此分析揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要參與者進行全面評估，包括市場佔有率、產品系列、策略舉措和財務表現。我們深入分析這些主要參與者的競爭動態和關鍵策略。

市場預測：基於歷史數據和當前市場狀況，我們對特定時期內的市場規模和成長趨勢進行預測。這包括定量分析和圖表展示，以展現未來的市場軌跡。

區域分析：這包括評估每個區域的市場表現，並識別關鍵市場和區域趨勢。它有助於了解區域市場動態和商業機會。

新趨勢與機會：識別當前及未來市場趨勢、技術創新和潛在投資領域。深入分析未來市場發展和成長前景。

客製化選項：我們提供靈活的客製化服務，可根據您的特定需求量身訂做報告。這包括額外的市場細分、國家/地區特定分析、競爭對手概況、自訂資料點以及針對特定細分市場的重點分析，從而更好地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章：市場波動因素、趨勢與框架

  • 市場歷史及展望
  • 滲透率和成長率預測：繪製圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 分析法規的影響
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球Remicade生物相似藥市場：依類型分類

  • 市場分析、洞察與預測
  • 100mg/10ml
  • 500mg/50ml

第5章：全球Remicade生物相似藥市場：依適應症分類

  • 市場分析、洞察與預測
  • 潰瘍性大腸炎
  • 類風濕性關節炎
  • 僵直性脊椎炎
  • 克隆氏症
  • 乾癬性關節炎
  • 斑塊型乾癬

第6章 全球Remicade生物相似藥市場：依應用分類

  • 市場分析、洞察與預測
  • 血液疾病
  • 癌症

第7章 全球Remicade生物相似藥市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novartis AG
    • Amgen Inc
    • Viatris Inc
    • Teva Pharmaceutical Industries Ltd
    • Biogen Inc
    • Merck & Co. Inc
    • LG Chem Ltd
    • Nippon Kayaku Co. Ltd
    • Celltrion Inc
    • Nichi-Iko Pharmaceutical Co. Ltd
    • Biocon Limited
    • Alvotech SA
    • MabPharm Ltd
    • Genor Biopharma Co. Ltd
    • Shanghai Biomabs Pharmaceuticals Co. Ltd
簡介目錄
Product Code: VMR11210446

The global Remicade biosimilar market size is expected to reach USD 42.32 Billion in 2034 from USD 5.56 Billion in 2025, growing at a CAGR of 25.29 during 2026-2034.This market is witnessing strong growth driven by increasing demand for cost-effective biologic therapies used in the treatment of autoimmune and inflammatory diseases. Remicade biosimilars provide therapeutic alternatives for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. Rising healthcare costs and growing pressure to improve treatment accessibility are encouraging healthcare systems to adopt biosimilar products. Regulatory support for biosimilar approvals is further contributing to market expansion.

Healthcare providers and payers are increasingly embracing biosimilars as they offer comparable efficacy and safety at lower costs than reference biologics. Growing awareness among physicians and patients regarding the benefits of biosimilars is supporting wider adoption. Expanding reimbursement coverage and favorable healthcare policies are also driving market growth. In addition, increasing prevalence of chronic inflammatory disorders continues to generate sustained demand for biologic therapies.

Future prospects remain highly promising as healthcare systems focus on cost containment and broader patient access to advanced treatments. Ongoing biosimilar development programs and regulatory harmonization efforts are expected to strengthen market competitiveness. Emerging economies are likely to become important growth regions due to expanding healthcare access and affordability initiatives. As biologic therapy utilization continues increasing, the Remicade biosimilar market is projected to experience sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • 100mg/10ml
  • 500mg/50ml

By Disease Indication

  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Crohn-(TM)s Disease
  • Psoriatic Arthritis
  • Plaque Psoriasis

By Application

  • Blood Disorders
  • Oncology Diseases

COMPANIES PROFILED

  • Novartis AG, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck & Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-Iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd., Shanghai Biomabs Pharmaceuticals Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL REMICADE BIOSIMILAR MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. 100mg/10ml Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. 500mg/50ml Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL REMICADE BIOSIMILAR MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Indication
  • 5.2. Ulcerative Colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Ankylosing Spondylitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Crohn-(TM)s Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Psoriatic Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Plaque Psoriasis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL REMICADE BIOSIMILAR MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Blood Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oncology Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL REMICADE BIOSIMILAR MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Disease Indication
    • 7.2.3 By Application
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Disease Indication
    • 7.3.3 By Application
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Disease Indication
    • 7.4.3 By Application
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Disease Indication
    • 7.5.3 By Application
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Disease Indication
    • 7.6.3 By Application
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL REMICADE BIOSIMILAR INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Novartis AG
    • 9.2.2 Amgen Inc
    • 9.2.3 Viatris Inc
    • 9.2.4 Teva Pharmaceutical Industries Ltd
    • 9.2.5 Biogen Inc
    • 9.2.6 Merck & Co. Inc
    • 9.2.7 LG Chem Ltd
    • 9.2.8 Nippon Kayaku Co. Ltd
    • 9.2.9 Celltrion Inc
    • 9.2.10 Nichi-Iko Pharmaceutical Co. Ltd
    • 9.2.11 Biocon Limited
    • 9.2.12 Alvotech S.A
    • 9.2.13 MabPharm Ltd
    • 9.2.14 Genor Biopharma Co. Ltd
    • 9.2.15 Shanghai Biomabs Pharmaceuticals Co. Ltd